ClinicalTrials.gg
CompletedNCT01817790Updated Apr 3, 2014Results posted

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

A Phase 3 interventional study of Fluticasone propionate and Placebo in Allergic Rhinitis and Seasonal Allergic Rhinitis, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-03.

Primary conditionRhinitis, Allergic, SeasonalRegistry: Rhinitis, AllergicReclassifiedWhy we changed it
Registry
Rhinitis, Allergic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Rhinitis, Allergic, Seasonal
Why
  1. The study's listed conditions name Rhinitis, Allergic, Seasonal, a narrower term within Rhinitis, Allergic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
626
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Seasonal.

Enrollment
8th of 28
626 · median 326
Started
2012
the only one that year
Phase 3
14 of 28
none open now
Registered
23rd of 28
by date
Lead sponsor
14 of 28
GlaxoSmithKline

Among the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 14 in phase 3, and was the 23rd registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

This study is designed to investigate the efficacy of fluticasone propionate (FP) on ocular symptoms associated with allergic rhinitis (AR).

Read the detailed description

While the current FP approved indication for GSK marketed formulation is limited to the treatment of nasal symptoms, several large well-controlled studies in which FP maintained adequate control of nasal symptoms when administered in a dose of 200 micrograms (mcg) once-daily (QD) also suggested improvement in ocular symptoms. This study will employ a randomized, double-blind, parallel group, multi-center design that compares FP and placebo nasal sprays in subjects with seasonal allergic rhinitis (SAR) to assess the effectiveness on ocular symptoms associated with AR.

03

Conditions studied

  • Allergic Rhinitis
  • Seasonal Allergic Rhinitis

Browse trials for

04

In context

Rhinitis, Allergic, Seasonal Reclassified

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

This study's enrollment of 626 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.

Browse Rhinitis, Allergic, Seasonal studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Rhinitis, Allergic, Seasonal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rhinitis, Allergic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with good general health (in the opinion of the investigator) with no and relevant abnormalities of medical history
  2. Participants with diagnosis of seasonal allergic rhinitis

    1. A clinical history (written or verbal confirmation) of allergic rhinitis with the seasonal onset and offset of nasal and ocular allergy symptoms during each of the last 2 mountain cedar pollen allergy seasons.
    2. A positive skin test reaction to (at least) the relevant allergen, mountain cedar pollen, as determined by the skin pricks method performed within 12 months of Visit 1).
  3. Participants with allergic rhinitis symptom of at least moderate severity for randomization:

    1. An iTOSS of ≥ 4 and an iNCSS of ≥2 on the morning of randomization (Visit 3/Baseline).
    2. An averaged (rTOSS) of ≥ 4, and an averaged rNCSS of ≥2 for three of the five days during the placebo lead in
  4. Participant residing within a geographical environment where exposure to mountain cedar pollen is significant during the entire study period.
  5. Participant demonstrates understanding of the study and willingness to participate as evidenced by voluntary written /assent and has received a signed and dated copy of the informed consent/assent form. Children, ages 12 to 17 will be required to sign an assent form as part of the informed consent process.

Exclusion criteria

Exclusion Criteria:

  1. Participants with known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  2. Participants with nasal disorders like:

    1. injury or surgery to their nose that the investigator believes would interfere with participation in the study.
    2. previously diagnosed with a severe physical obstruction of the nose (e.g., deviated septum) that could affect the deposition of double-blind intranasal study drug.
    3. Rhinitis medicamentosa
  3. Participants who have historical or current evidence of uncontrolled disease like asthma, cardiac arrhythmias, hypertension, diabetes mellitus, ocular herpes, glaucoma, hepatic or renal disease, etc.
  4. Presence of or symptoms of an active bacterial or viral infection.
  5. Participants who have conjunctivitis caused by an infectious agent.
  6. Participants with current, single eye or bilateral cataracts or participants who had cataract surgery within/less than 3 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
626 participants (actual)

Study arms

  • Experimental
    Fluticasone propionate nasal spray

    Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.

    Drug: Fluticasone propionate

  • Placebo comparator
    Placebo nasal spray

    Two sprays of placebo per nostril to be administered in morning.

    Drug: Placebo

Interventions

  • Nasal spray formulation (200 mcg/day)

    Also known as: Flonase

  • DrugPlacebo

    Vehicle for Fluticasone propionate aqueous nasal spray

07

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS)

    The Reflective Total Ocular Symptom Score (rTOSS) is the sum of 3 individual participant-assessed symptom scores (eye itching/burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. Subjects completed rTOSS in the evening (PM rTOSS; 12 hours post morning nasal spray use) and once in the morning (AM score: prior to nasal spray use). Daily (i.e. during one dosing interval) rTOSS is defined as the average of the PM rTOSS and the AM rTOSS of the next day prior to AM dosing. The mean change from baseline in (daily, AM, PM) TOSS was calculated as the subject's treatment period mean (over 14 days; from Day 0 PM to Day 14 AM) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

Secondary outcomes

  1. Mean Change From Baseline in AM rTOSS

    rTOSS is the sum of 3 individual participant-assessed symptom scores (eye itching/ burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For AM rToss, subjects completed rTOSS in the morning (AM score: prior to nasal spray use). The mean change from baseline in AM rTOSS was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

  2. Mean Change From Baseline in PM rTOSS

    rTOSS is the sum of 3 individual participant-assessed symptom scores (eye itching/ burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For PM rTOSS, subjects completed rTOSS in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM rTOSS was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

  3. Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Itching/Burning

    The AM Reflective Ocular Symptom Score was assessed individually for eye itching/burning using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye itching and burning) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

  4. Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Itching/Burning

    The PM Reflective Ocular Symptom Score was assessed individually for eye itching/burning using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye itching and burning) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

  5. Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Tearing/Watering

    The AM Reflective Ocular Symptom Score was assessed individually for eye tearing/watering using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye tearing/watering) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

  6. Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Tearing/Watering

    The PM Reflective Ocular Symptom Score was assessed individually for eye tearing/watering using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye tearing/watering) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

  7. Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Redness

    The AM Reflective Ocular Symptom Score was assessed individually for eye redness using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye redness) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

  8. Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Redness

    The PM Reflective Ocular Symptom Score was assessed individually for eye redness using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye redness) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

  9. Mean Change From Baseline in AM Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS)

    Instantaneous total ocular symptom scores (iTOSS) assessments are self perceived evaluation of symptom severity immediately before the dose (how the subject feels at that point in time). iTOSS (possible score of 0-9) is the sum of 3 individual participant-assessed symptom scores for eye itching/burning, eye tearing/watering, and eye redness each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Mean changes from baseline were calculated as treatment period iTOSS minus baseline iTOSS.

    Time frame: Baseline to 14 days

  10. Mean Change From Baseline in Reflective Nasal Congestion Symptom Score (rNCSS)

    The rNCSS is a participant perceived evaluation of overall congestion symptom severity (evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe) which was completed once in the evening (PM), and once in the morning (AM). rNCSS is defined as the average of the PM rNCSS and the AM rNCSS of the next day prior to AM dosing. The mean change from baseline in rNCSS (daily, AM, PM)was calculated as the subject's treatment period mean (over 14 days; from Day 0 PM to Day 14 AM) minus the baseline period (placebo run-in) mean.

    Time frame: Baseline to 14 days

  11. End-of-treatment Assessment of Response to Therapy for Ocular Symptoms

    Overall response to therapy assessment was done using a 7-point categorical scale in which participants rated their response to therapy as follows: +3 = Significantly Improved; +2 = Moderately Improved; +1 = Mildly Improved; 0 = No Change; -1= Mildly Worse; -2 = Moderately Worse; -3 = Significantly Worse.

    Time frame: Day 14

  12. Mean Change in Objective Assessment of Conjunctival Redness

    Conjunctival redness was evaluated as a clinical sign of SAR by the investigator. Scoring of severity was rated according to a 4-point scale: 0 = normal; 1 = Slightly pink; 2 = Moderately pink, some dilation; 3 = Intense red vessels, dilated.

    Time frame: Baseline to 14 days

  13. Mean Changes From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Scores

    MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. It measures five domains of functional impairment that are most important to subjects with SAR: practical problems, nasal symptoms, eye symptoms, activity limitations, and other symptoms. Participants scored their degree of impairment on a seven-point scale. (0 - 6). Mini RQLQ final score is the average of sub-scales, ranges from 0 (best possible outcome) to 6 (worst possible outcome).

    Time frame: Baseline to 14 days

  14. Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Activities

    MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. Activity limitations is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

    Time frame: Baseline to 14 days

  15. Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Practical Problems

    MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. 'Practical Problems' is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

    Time frame: Baseline to 14 days

  16. Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Nose Symptoms

    MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Nose Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

    Time frame: Baseline to 14 days

  17. Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Eye Symptoms

    MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Eye Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

    Time frame: Baseline to 14 days

  18. Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Other Symptoms

    MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Other Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

    Time frame: Baseline to 14 days

08

Results

Posted Apr 3, 2014

Participant flow

Participants were recruited at 6 clinical sites in the US.

Participant flow — Overall Study
MilestoneFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Started314312
Completed310304
Not completed48
Withdrew: Adverse event02
Withdrew: Lost to follow-up01
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject13
Withdrew: Other: could not attend appointment11

Outcome measures

PrimaryMean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS)

The Reflective Total Ocular Symptom Score (rTOSS) is the sum of 3 individual participant-assessed symptom scores (eye itching/burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. Subjects completed rTOSS in the evening (PM rTOSS; 12 hours post morning nasal spray use) and once in the morning (AM score: prior to nasal spray use). Daily (i.e. during one dosing interval) rTOSS is defined as the average of the PM rTOSS and the AM rTOSS of the next day prior to AM dosing. The mean change from baseline in (daily, AM, PM) TOSS was calculated as the subject's treatment period mean (over 14 days; from Day 0 PM to Day 14 AM) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS)
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS)-0.91 ± 1.625-0.63 ± 1.525
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0024 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.36 · 95% CI -0.59 to -0.13Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Change From Baseline in AM rTOSS

rTOSS is the sum of 3 individual participant-assessed symptom scores (eye itching/ burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For AM rToss, subjects completed rTOSS in the morning (AM score: prior to nasal spray use). The mean change from baseline in AM rTOSS was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in AM rTOSS
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in AM rTOSS-0.96 ± 1.627-0.68 ± 1.573
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0057 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.33 · 95% CI -0.56 to -0.10Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Change From Baseline in PM rTOSS

rTOSS is the sum of 3 individual participant-assessed symptom scores (eye itching/ burning, eye tearing/watering, and eye redness), each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For PM rTOSS, subjects completed rTOSS in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM rTOSS was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in PM rTOSS
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in PM rTOSS-0.87 ± 1.735-0.60 ± 1.577
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0009 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.41 · 95% CI -0.65 to -0.17Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Itching/Burning

The AM Reflective Ocular Symptom Score was assessed individually for eye itching/burning using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye itching and burning) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Itching/Burning
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Itching/Burning-0.35 ± 0.581-0.28 ± 0.553
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0117 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.10 · 95% CI -0.19 to -0.02Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Itching/Burning

The PM Reflective Ocular Symptom Score was assessed individually for eye itching/burning using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye itching and burning) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Itching/Burning
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Itching/Burning-0.33 ± 0.626-0.24 ± 0.554
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0005 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.15 · 95% CI -0.23 to -0.06Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Tearing/Watering

The AM Reflective Ocular Symptom Score was assessed individually for eye tearing/watering using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye tearing/watering) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Tearing/Watering
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Tearing/Watering-0.35 ± 0.596-0.24 ± 0.589
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0023 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.13 · 95% CI -0.22 to -0.06
SecondaryMean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Tearing/Watering

The PM Reflective Ocular Symptom Score was assessed individually for eye tearing/watering using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye tearing/watering) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Tearing/Watering
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Tearing/Watering-0.32 ± 0.653-0.19 ± 0.586
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = <0.0001 (p-value was nor adjusted for multiple comparisons.) · Least square mean difference: -0.18 · 95% CI -0.26 to -0.09Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Redness

The AM Reflective Ocular Symptom Score was assessed individually for eye redness using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the morning, prior to nasal spray use. The mean change from baseline in AM Reflective Ocular Symptom Score (eye redness) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Redness
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Redness-0.26 ± 0.597-0.17 ± 0.613
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0304 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.10 · 95% CI -0.18 to -0.01Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Redness

The PM Reflective Ocular Symptom Score was assessed individually for eye redness using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe, for a possible score of 0-9. For evaluation, subjects completed the scoring in the evening, 12 hours post morning nasal spray use. The mean change from baseline in PM Reflective Ocular Symptom Score (eye redness) was calculated as the subject's treatment period mean (over 14 days) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Redness
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Redness-0.22 ± 0.628-0.17 ± 0.635
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0361 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.10 · 95% CI -0.19 to -0.01Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Change From Baseline in AM Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS)

Instantaneous total ocular symptom scores (iTOSS) assessments are self perceived evaluation of symptom severity immediately before the dose (how the subject feels at that point in time). iTOSS (possible score of 0-9) is the sum of 3 individual participant-assessed symptom scores for eye itching/burning, eye tearing/watering, and eye redness each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. Mean changes from baseline were calculated as treatment period iTOSS minus baseline iTOSS.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in AM Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS)
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in AM Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS)-0.80 ± 1.443-0.55 ± 1.531
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0129 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.28 · 95% CI -0.50 to -0.06Linear Fixed-effect Model; treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Change From Baseline in Reflective Nasal Congestion Symptom Score (rNCSS)

The rNCSS is a participant perceived evaluation of overall congestion symptom severity (evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe) which was completed once in the evening (PM), and once in the morning (AM). rNCSS is defined as the average of the PM rNCSS and the AM rNCSS of the next day prior to AM dosing. The mean change from baseline in rNCSS (daily, AM, PM)was calculated as the subject's treatment period mean (over 14 days; from Day 0 PM to Day 14 AM) minus the baseline period (placebo run-in) mean.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Reflective Nasal Congestion Symptom Score (rNCSS)
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change From Baseline in Reflective Nasal Congestion Symptom Score (rNCSS)-0.34 ± 0.547-0.20 ± 0.443
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.0002 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.14 · 95% CI -0.22 to -0.07Linear Fixed-effect Model; treatment and site as fixed factors and baseline score as covariate.
SecondaryEnd-of-treatment Assessment of Response to Therapy for Ocular Symptoms

Overall response to therapy assessment was done using a 7-point categorical scale in which participants rated their response to therapy as follows: +3 = Significantly Improved; +2 = Moderately Improved; +1 = Mildly Improved; 0 = No Change; -1= Mildly Worse; -2 = Moderately Worse; -3 = Significantly Worse.

Time frame:
Day 14
Reported as:
Number · Participants
End-of-treatment Assessment of Response to Therapy for Ocular Symptoms
ParticipantsFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Significantly improved2216
Moderately Improved7659
Mildly Improved7971
No change8197
Mildly Worse2120
Moderatly Worse2424
Significantly Worse1022
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · Cochran-Mantel-Haenszel · p = 0.0118 (p-value was not adjusted for multiple comparisons.)Using this test controlling for investigative site. The response variable lied on ordinal scale of measurement.
SecondaryMean Change in Objective Assessment of Conjunctival Redness

Conjunctival redness was evaluated as a clinical sign of SAR by the investigator. Scoring of severity was rated according to a 4-point scale: 0 = normal; 1 = Slightly pink; 2 = Moderately pink, some dilation; 3 = Intense red vessels, dilated.

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Change in Objective Assessment of Conjunctival Redness
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Change in Objective Assessment of Conjunctival Redness-0.20 ± 0.815-0.15 ± 0.736
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = 0.8586 · Least square mean difference: -0.01 · 95% CI -0.12 to 0.10
SecondaryMean Changes From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Scores

MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. It measures five domains of functional impairment that are most important to subjects with SAR: practical problems, nasal symptoms, eye symptoms, activity limitations, and other symptoms. Participants scored their degree of impairment on a seven-point scale. (0 - 6). Mini RQLQ final score is the average of sub-scales, ranges from 0 (best possible outcome) to 6 (worst possible outcome).

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Changes From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Scores
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Changes From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Scores-0.98 ± 1.311-0.49 ± 1.091
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = <0.0001 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.47 · 95% CI -0.65 to -0.29Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Activities

MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. Activity limitations is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Activities
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Activities-0.93 ± 1.384-0.39 ± 1.269
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = <0.0001 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.49 · 95% CI -0.68 to -0.30Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Practical Problems

MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. 'Practical Problems' is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Practical Problems
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Practical Problems-1.04 ± 1.476-0.57 ± 1.258
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = <0.0001 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.44 · 95% CI -0.64 to -0.24Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Nose Symptoms

MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Nose Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Nose Symptoms
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Nose Symptoms-1.09 ± 1.456-0.50 ± 1.257
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = <0.0001 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.53 · 95% CI -0.73 to -0.33Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Eye Symptoms

MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Eye Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Eye Symptoms
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Eye Symptoms-0.98 ± 1.512-0.55 ± 1.284
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = <0.0001 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.44 · 95% CI -0.65 to -0.23Linear Fixed-effect Model; Treatment and site as fixed factors and baseline score as covariate.
SecondaryMean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Other Symptoms

MiniRQLQ is a 14-item, disease-specific instrument for assessing the impact of allergic rhinitis on activities of daily living and overall well-being. "Other Symptoms" is one of the domains of Mini RQLQ scores. Participants scored their degree of impairment on a seven-point scale (0 = not troubled, 6 = extremely troubled).

Time frame:
Baseline to 14 days
Reported as:
Mean · Score on a scale
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Other Symptoms
Score on a scaleFluticasone Propionate Nasal SprayPlacebo Nasal Spray
Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Other Symptoms-0.89 ± 1.607-0.48 ± 1.294
Statistical analysis
  • Fluticasone Propionate Nasal Spray vs Placebo Nasal Spray · ANCOVA · p = <0.0001 (p-value was not adjusted for multiple comparisons.) · Least square mean difference: -0.42 · 95% CI -0.64 to -0.21

Adverse events

Collected over Participants were followed for the duration of study, an average of 3 weeks.. Non-serious events are listed at a 0.3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Propionate Nasal Spray—0/314 (0%)8/314 (2.5%)
Placebo Nasal Spray—0/312 (0%)8/312 (2.6%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventFluticasone Propionate Nasal SprayPlacebo Nasal Spray
PyrexiaGeneral disorders1/3142/312
BronchitisInfections and infestations0/3142/312
HeadacheNervous system disorders2/3140/312
PainGeneral disorders0/3141/312
InfluenzaInfections and infestations0/3141/312
MigraineNervous system disorders0/3141/312
EpistaxisRespiratory, thoracic and mediastinal disorders0/3141/312
Respiratory Tract CongestionRespiratory, thoracic and mediastinal disorders0/3141/312
HypersensitivityImmune system disorders0/3141/312
DermatitisSkin and subcutaneous tissue disorders0/3141/312

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fluticasone Propionate Nasal SprayPlacebo Nasal SprayTotal
Mean40.4 ± 14.5540.5 ± 16.3640.5 ± 15.47
Sex: Female, Male
Sex: Female, Male(Participants)Fluticasone Propionate Nasal SprayPlacebo Nasal SprayTotal
Female212201413
Male102111213
09

Study locations

1 site
  • PPD Corporate Headquarters
    Wilmington, North Carolina 28401-3331, United States
10

References and documents

Publications

  • Ratner P, Van Bavel J, Mohar D, Jacobs RL, Hampel F, Howland W, Karwal R. Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2015 Feb;114(2):141-7. doi: 10.1016/j.anai.2014.11.012. PubMed 25624132 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2013
First posted
Mar 25, 2013
Start
Dec 2012
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Apr 3, 2014
Last update
Apr 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01817790
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 25, 2013
Start date
Dec 2012
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Apr 3, 2014
Last update
Apr 3, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion